Singapore Lung Cancer Therapeutics Market Report 2022 to 2030

Singapore Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Singapore Lung Cancer Therapeutics Market will reach a value of $70 Mn from $36 Mn in 2022, growing at a CAGR of 8.7% during 2022-2030. The Lung Cancer Therapeutics Market in Singapore is dominated by a few domestic pharmaceutical companies such as Roche Singapore, ASTAR Biomedical, and National Cancer Centre Singapore. The Lung Cancer Therapeutics Market in Singapore is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Singapore lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10SGPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Dr. Vishwa Modhia

Buy Now

Singapore Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Singapore Lung Cancer Therapeutics market will reach a value of $70 Mn from $36 Mn in 2022, growing at a CAGR of 8.7% during 2022-2030.

Singapore is a small island city-state in Southeast Asia, with a multiracial population of 5.7 Mn people, comprising 76% Chinese, 15% Malays, and 9% Indians and other races. Lung cancer presents a significant health challenge to the ageing population. In Singapore, lung cancer is the second most prevalent cancer in men and the third most common cancer in women. Between 2013 and 2017, there were 7780 new cases of lung cancer diagnosed in Singapore, making it the top cause of cancer mortality in males and the second largest cause of cancer death in women. Personalized medicine necessitates more extensive molecular testing as well as the use of artificial intelligence in machine learning. Both have resulted in a tremendous rise in bioinformatics data. To deal with this altering landscape, Singapore's healthcare personnel will need to embrace these changes and continue to learn on the job.

According to the latest WHO data published in 2020 Lung Cancers Deaths in Singapore reached 1,540 or 6.48% of total deaths. The age-adjusted Death Rate is 17.56 per 100,000 population ranks Singapore 69^th in the world. Singapore's government spends 6.1% of its GDP on healthcare.

Singapore Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Weekly tumour board meetings in public cancer facilities involve a multidisciplinary team to discuss difficult cases and find a consensus on management. Many of the experts that advise on these tumour boards have a special interest or sub-specialisation in lung cancer. In Singapore, traditional video-assisted thoracoscopic surgery (VATS) has been conducted since the early 2000s, and robotic-assisted thoracoscopic surgery has been performed since the late 2000s. Radiotherapy practice for lung cancer is consistent across all centres. These aspects could boost the Singapore Lung Cancer Therapeutics market.

Market Restraints

Healthcare providers rely on guidelines produced by larger countries with a broader spectrum of lung cancer. The clustering of the national health care system poses obstacles in terms of service centralization, interinstitutional training, collaboration, and standardisation. Singapore currently lacks a national lung cancer screening programme. Singapore is dealing with difficulties such as skilled labour scarcity, housing shortages, and an ageing population. It relies largely on exports and imports. These factors may deter new entrants into the Singapore Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Roche Singapore Pte: Roche Singapore is a subsidiary of the Swiss pharmaceutical company Roche, which produces and distributes a range of medicines, including those used in the treatment of lung cancer
ASTAR Biomedical Research Council: ASTAR is a Singaporean biomedical research organization that conducts research into a range of diseases, including lung cancer, and develops therapeutics for these conditions
National Cancer Centre Singapore: The National Cancer Centre Singapore is a government-funded institution that specializes in cancer research, treatment, and education, including the development of lung cancer therapeutics
Pfizer Pte: Pfizer Singapore is a subsidiary of the American pharmaceutical company Pfizer, which produces and distributes a range of medicines, including those used in the treatment of lung cancer

Recent Notable Updates

June 2022: Fosun Pharmaceutical, the pharmaceutical branch of China billionaire Guo Guangchang's investment firm Fosun International, will pay up to $158 Mn for a 60 % ownership in one of Singapore's top cancer treatment facility operators. OncoCare Medical operates seven clinics in major private medical centres in Singapore, including the city-only state's private medical oncology medical facility for women. The investment will help Fosun Pharma expand its medical services business in Southeast Asia and boost its cancer treatment services overall.

Healthcare Policies and Reimbursement Scenarios

The Health Sciences Authority (HSA) and the Ministry of Health supervise the regulation and reimbursement of lung cancer medicines in Singapore. In addition, Singaporeans are enrolled in a basic health insurance plan through Medisave, a national medical savings scheme in which a portion of earnings is set aside for an individual's future health care. To be reimbursed, lung cancer medicines must be on the Standard Drug List (SDL), which is a list of pharmaceuticals recognised for payment by the Ministry of Health. The Singapore Health Sciences Authority's Cell Therapy Facility (HSA-CTF), which is part of the HSA's Blood Services Group, adheres to current Good Manufacturing Practice (GMP) standards.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.